JPWO2022114908A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022114908A5
JPWO2022114908A5 JP2023532339A JP2023532339A JPWO2022114908A5 JP WO2022114908 A5 JPWO2022114908 A5 JP WO2022114908A5 JP 2023532339 A JP2023532339 A JP 2023532339A JP 2023532339 A JP2023532339 A JP 2023532339A JP WO2022114908 A5 JPWO2022114908 A5 JP WO2022114908A5
Authority
JP
Japan
Prior art keywords
acid
pharmaceutical formulation
oral pharmaceutical
moiety
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023532339A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023551480A (ja
JP2023551480A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/KR2021/017802 external-priority patent/WO2022114908A1/ko
Publication of JP2023551480A publication Critical patent/JP2023551480A/ja
Publication of JPWO2022114908A5 publication Critical patent/JPWO2022114908A5/ja
Publication of JP2023551480A5 publication Critical patent/JP2023551480A5/ja
Pending legal-status Critical Current

Links

JP2023532339A 2020-11-27 2021-11-29 ビオチン部分、脂肪酸部分またはその組合せを連結されて有する生物学的活性材料結合体の経口製剤 Pending JP2023551480A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20200163362 2020-11-27
KR10-2020-0163362 2020-11-27
PCT/KR2021/017802 WO2022114908A1 (ko) 2020-11-27 2021-11-29 비오틴 모이어티, 지방산 모이어티 또는 이의 조합이 결합된 생리활성 물질 접합체의 경구 제형

Publications (3)

Publication Number Publication Date
JP2023551480A JP2023551480A (ja) 2023-12-08
JPWO2022114908A5 true JPWO2022114908A5 (https=) 2024-11-28
JP2023551480A5 JP2023551480A5 (https=) 2024-11-28

Family

ID=81756220

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023532339A Pending JP2023551480A (ja) 2020-11-27 2021-11-29 ビオチン部分、脂肪酸部分またはその組合せを連結されて有する生物学的活性材料結合体の経口製剤

Country Status (11)

Country Link
US (1) US20240000803A1 (https=)
EP (1) EP4252781A1 (https=)
JP (1) JP2023551480A (https=)
KR (1) KR20220075189A (https=)
CN (1) CN116940384A (https=)
AU (2) AU2021385222B2 (https=)
CA (1) CA3200351A1 (https=)
GB (1) GB2616223B (https=)
IL (1) IL303023A (https=)
MX (1) MX2023006189A (https=)
WO (1) WO2022114908A1 (https=)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569901B2 (en) * 2000-01-28 2003-05-27 Novo Nordisk A/S Alkynyl-substituted propionic acid derivatives, their preparation and use
GB0308734D0 (en) * 2003-04-15 2003-05-21 Axcess Ltd Uptake of macromolecules
KR20080042045A (ko) * 2005-05-23 2008-05-14 에스디지,인코포레이티드 포유동물로의 인터페론 전달용 지질 구조물
PL1767545T3 (pl) * 2005-09-22 2010-04-30 Biocompatibles Uk Ltd Polipeptydy fuzyjne GLP-1 (glukagonopodobny peptyd-1) o zwiększonej odporności na peptydazy
US8962015B2 (en) * 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
KR100864584B1 (ko) * 2008-02-25 2008-10-24 성균관대학교산학협력단 비오틴으로 수식된 엑센딘 유도체, 이의 제조방법 및 이의용도
CN102037008B (zh) * 2008-03-18 2016-08-31 诺沃-诺迪斯克有限公司 蛋白酶稳定化的、酰化胰岛素类似物
EP2751291B1 (en) * 2011-09-01 2018-08-15 University of Southern California Methods for preparing high throughput peptidomimetics, orally bioavailable drugs and compositions containing same
AU2014282802B2 (en) * 2013-06-18 2019-12-05 Transgene Biotek Tld Pharmaceutical formulations and methods for oral delivery of biologically active ingredient
AU2014364589B2 (en) * 2013-12-18 2020-02-27 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
KR20180039726A (ko) * 2015-09-04 2018-04-18 더 캘리포니아 인스티튜트 포 바이오메디칼 리써치 인슐린 면역글로불린 융합 단백질
CR20200185A (es) * 2017-10-31 2020-06-19 Medimmune Ltd Administración oral de análogos del péptido glp-1

Similar Documents

Publication Publication Date Title
RU2559540C2 (ru) Дважды ацилированные производные glp-1
JP4698579B2 (ja) 可逆的peg化薬物
ES2725808T3 (es) Derivados de PEG que contienen dos cadenas de PEG
US7153930B1 (en) Peptide transport
RU2388765C2 (ru) Натрийуретические соединения, конъюгаты и их применение
TWI508737B (zh) 具有延長的活體內功效的生長激素
TWI770010B (zh) 聚乙二醇衍生物及其用途
RU2004119437A (ru) 17α-АЛКИЛ-17β-ОКСИЭСТРАТРИЕНЫ И ПРОМЕЖУТОЧНЫЕ ПРОДУКТЫ ДЛЯ ИХ ПОЛУЧЕНИЯ, ПРИМЕНЕНИЕ 17α -АЛКИЛ-17β -ОКСИЭСТРАТРИЕНОВ ДЛЯ ПОЛУЧЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ, А ТАКЖЕ ФАРМАЦЕВТИЧЕСКИХ ПРЕПАРАТОВ
JP2008507477A (ja) ポリペプチド延長タグ
IL128332A (en) Glucagon-like insulinotropic peptides analogues, preparations containing them and uses
EP3463293A1 (fr) Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5, une insuline prandiale et/ou une hormone gastrointestinale, et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
CZ20031566A3 (cs) Farmaceutické přípravky pro perorální podávání farmakologicky účinných látek
CN1956735A (zh) 用于增强治疗剂黏膜吸收的递送剂
CA2449320A1 (en) Mixtures of growth hormone drug-oligomer conjugates compromising polyalkylene glycol, uses thereof, and methods of making same
JP2023504184A (ja) ペプチドコンジュゲートおよび使用方法
JP2002531543A5 (https=)
JP7411189B2 (ja) 分岐型分解性ポリエチレングリコール結合体
JPWO2022114908A5 (https=)
RU2023116635A (ru) Пероральный состав конъюгата биологически активного материала содержащего фрагмент биотина, фрагмент жирной кислоты или их комбинацию, связанную с ним
AU2024335696A1 (en) Stable glp-1 analogs for the treatment of human disease and disorders
RU2023116634A (ru) Конъюгат биологически активного материала, содержащий фрагмент биотина, фрагмент жирной кислоты или их комбинацию, связанную с ним
AU2021385222B2 (en) Oral formulation of biologically active material conjugate having biotin moiety, fatty acid moiety, or combination thereof coupled thereto
JPWO2020242268A5 (https=)
RU2860768C2 (ru) Пероральный состав конъюгата биологически активного материала, содержащего фрагмент биотина, фрагмент жирной кислоты или их комбинацию, связанную с ним
JP2008545644A (ja) 新規ポリ(エチレングリコール)誘導体とタンパク質へのそのカップリング方法